Characteristics and outcomes of anti-Ku antibody–associated interstitial lung disease: a retrospective study of 60 patients
Authors' conclusion
ILD occurred in 39% of anti-Ku-positive patients and progressed in 75% of them
Study context
- Population
- Anti-Ku antibody-positive patients with interstitial lung disease (ILD), 10 French University Hospitals, January 2010 to June 2025of 154 anti-Ku-positive patients
- Participants
- 60 patients
- Outcome
- ILD progression (criteria inspired by ATS/ERS/JRS/ALAT guidelines, applied across entire follow-up)
Methodological detailsobservational, multicentre, 10 French University Hospitals, Cox proportional hazards models
- Observational
- Multicentre
- 10 French University Hospitals
- Cox proportional hazards models
Main finding
As reported in the abstract
ILD progression
ILD in anti-Ku-positive patients
60
39%
Patients progressed
45
75%
Median time to progression, years
4
2–11
Male sex associated with ILD progression, aHR
2.7 (1.4 to 5.2) (95% CI)
Observational data: associations, not effects.
Further findings
Predominant ILD pattern: fibrotic non-specific interstitial pneumonia
- Fibrotic NSIP
- 27%, n=16
ILD present at AID diagnosis
- ILD at AID diagnosis
- 48 (80%)
Progressive fibrosing ILD with strict 12-month cut-off
- Patients fulfilling definition
- 6
Baseline pulmonary fibrosis and survival
- Baseline pulmonary fibrosis
- 34 (57%)
- Reduced survival with baseline fibrosis, aHR
- 6.5 (1.5 to 28.2) (95% CI)
- Adjusted for age at ILD diagnosis and cardiac involvement
Original publication
Characteristics and outcomes of anti-Ku antibody–associated interstitial lung disease: a retrospective study of 60 patients. RMD Open. Published 27 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →